[Skip to Content]

diabetic macular oedema

Response to NICE announcing their positive draft final guidance for EYLEA® for the treatment of visual impairment due to diabetic macular oedema (DMO)

The Royal College of Ophthalmologists welcomes the draft Final Appraisal Determination (FAD) from NICE recommending EYLEA (aflibercept) as a treatment option for patients with visual impairment due to diabetic macular oedema (DMO) and a central retinal thickness of >400 micrometers. We hope that this decision will become final and that clinical commissioning groups will support

Review of ranibizumab in patients with diabetic macular oedema

Statement on the rapid review of the technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema (DMO) Review of Ranibizumab for DMO